BOUCHERVILLE, QC, April 15, 2026 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, announced today it will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference for the third consecutive year. Mr. Roberge, President and CEO, will make a presentation on April 21 at 16:00 EST, and will be available for one-on-one meetings throughout the conference.
Event: | 2026 Bloom Burton & Co. Healthcare Investor Conference
|
Date | April 21 -22, 2026
|
Location | Metro Toronto Convention Center, Ontario |
Presentation: | April 21 - 16:00 EST |
A live and recorded webcast of the LSL Pharma presentation will be available on the "Information for Investors" section of LSL Pharma Group corporate website www.groupelslpharma.com or at the following link:
https://event.summitcast.com/view/7Mc8ivebFGUgA8YD45rSGK/kkEogebCPhBRF9cjybbQCq
For more information on the "2026 Bloom Burton & Co. Healthcare Investor Conference" or to register, please follow this link: https://www.bloomburton.com/conference/
ABOUT THE CONFERENCE
The Bloom Burton & Co. Healthcare Investor Conference brings together American, Canadian and international investors interested in the latest developments in Canadian healthcare companies. Participants will have the opportunity to obtain up-to-date information on leading Canadian public and private companies, through presentations and private meetings.
ABOUT LSL PHARMA GROUP INC.
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Leveraging its technical expertise, certified facilities, and experienced team, LSL Pharma delivers high-quality solutions that meet the highest industry standards. The wholly-owned subsidiaries of LSL Pharma include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc., Dermolab Pharma Ltd., Laboratoire Du-Var Inc. and Juno OTC Inc. For more information, please visit our website at www.groupelslpharma.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has reviewed and does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Groupe LSL PHARMA INC.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2026/15/c1239.html
François Roberge, President and Chief Executive Officer, (514) 664-7700, E-mail : Investors@groupelslpharma.com